Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group
暂无分享,去创建一个
F. Solé | M. L. Le Beau | T. Brümmendorf | K. Götze | P. Greenberg | M. Slovak | W. Hofmann | L. Trümper | J. Bennett | M. Lübbert | C. Fonatsch | P. Valent | M. Pfeilstöcker | W. Sperr | U. Germing | A. Giagounidis | U. Platzbecker | R. Stauder | K. Ohyashiki | F. Nolte | C. Aul | T. Nösslinger | D. Haase | J. Schanz | B. Hildebrandt | H. Tüchler | C. Müller-Thomas | M. Mallo | K. Shirneshan | F. Braulke
[1] R. Schlenk,et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. , 2014, Leukemia research.
[2] R. Schlenk,et al. Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. , 2013, Leukemia research.
[3] A. Mishra,et al. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes , 2013, American journal of hematology.
[4] M. Cazzola,et al. P-113 Revised International Prognostic Scoring System (IPSS-R) for primary treated myelodysplastic syndromes (MDS) patients: A report from the IWG-PM , 2013 .
[5] M. Breccia,et al. Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine , 2013, Annals of Hematology.
[6] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[7] F. Solé,et al. Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia? , 2012, Leukemia research.
[8] Hui Jiang,et al. The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure. , 2012, Leukemia research.
[9] C. Steidl,et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Tubbs,et al. Diagnostic yield of bone marrow and peripheral blood FISH panel testing in clinically suspected myelodysplastic syndromes and/or acute myeloid leukemia: a prospective analysis of 433 cases. , 2011, American journal of clinical pathology.
[11] E. Estey,et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] E. Campo,et al. Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do? , 2010, Leukemia research.
[13] L. Trümper,et al. FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients. , 2010, Leukemia research.
[14] G. Bhagat,et al. FISH analysis in addition to G-band karyotyping: utility in evaluation of myelodysplastic syndromes? , 2010, Leukemia research.
[15] R. Pinheiro,et al. Comparison of I-FISH and G-banding for the detection of chromosomal abnormalities during the evolution of myelodysplastic syndrome. , 2009, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[16] Valeria Santini,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.
[17] Thomas H Müller,et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.
[18] T. Haferlach,et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. , 2007, Leukemia research.
[19] Jean McGowan-Jordan,et al. ISCN 2013 : an international system for human cytogenetic nomenclature (2013) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature , 2005 .
[20] L. Rimsza,et al. Efficacy of lenalidomide in myelodysplastic syndromes. , 2005, The New England journal of medicine.
[21] P. Fenaux. Myelodysplastic syndromes: From pathogenesis and prognosis to treatment. , 2004, Seminars in hematology.
[22] M. Silva,et al. Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. , 2002, Leukemia research.
[23] A. Cuneo,et al. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype , 2001, Leukemia.
[24] C. Bloomfield,et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997. , 2000, The hematology journal : the official journal of the European Haematology Association.
[25] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[27] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .